Small‐Molecule Stabilization of the 14‐3‐3/Gab2 Protein–Protein Interaction (PPI) Interface. (8th December 2015)

• Record Type: Journal Article
• Authors: Bier, David; Bartel, Maria; Sies, Katharina; Halbach, Sebastian; Higuchi, Yusuke; Haranosono, Yu; Brummer, Tilman; Kato, Nobuo; Ottmann, Christian
• Is Part Of: ChemMedChem. Volume 11:Number 8(2016)
• Page Start: 911
• Page End: 918
• Publication Date: 2015-12-08
• Subjects: natural products -- protein–protein interactions -- semi-synthesis -- small molecules -- X-ray protein crystallography; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201500484
• Languages: English
• ISSNs: 1860-7179

Abstract

Abstract: Small‐molecule modulation of protein–protein interactions (PPIs) is one of the most promising new areas in drug discovery. In the vast majority of cases only inhibition or disruption of PPIs is realized, whereas the complementary strategy of targeted stabilization of PPIs is clearly under‐represented. Here, we report the example of a semi‐synthetic natural product derivative—ISIR‐005—that stabilizes the cancer‐relevant interaction of the adaptor protein 14‐3‐3 and Gab2. The crystal structure of ISIR‐005 in complex with 14‐3‐3 and the binding motif of Gab2 comprising two phosphorylation sites (Gab2pS210pT391) showed how the stabilizing molecule binds to the rim‐of‐the‐interface of the protein complex. Only in the direct vicinity of 14‐3‐3/Gab2pT391 site is a pre‐formed pocket occupied by ISIR‐005; binding of the Gab2pS210 motif to 14‐3‐3 does not create an interface pocket suitable for the molecule. Accordingly, ISIR‐005 only stabilizes the binding of the Gab2pT391 but not the Gab2pS210 site. This study represents structural and biochemical proof of the druggability of the 14‐3‐3/Gab2 PPI interface with important implications for the development of PPI stabilizers. Abstract : A stabilizing influence : We have identified a semi‐synthetic, natural product protein–protein interaction (PPI) stabilizer that enhances the binding of the adapter protein 14‐3‐3 to oncogenic Gab2. Stabilization of this PPI is expected to attenuate the pro‐oncogenic activity of Gab2. Our molecule, ISIR‐005, represents chemical proof‐of‐principle for the druggability of the 14‐3‐3/Gab2 interface.